Biogen, Elan combine on major drug
Article Abstract:
Pharmaceutical manufacturer and biotechnology company Biogen Inc has announced a joint effort with Dublin, Ireland-based Elan to develop, produce and market a drug named Antegren, which both claim has the 'blockbuster' potential to fight a variety of diseases. Terms of the agreement were undisclosed. The companies say that the drug has already shown promising results in clinical testing in treating multiple sclerosis, and Crohn's disease. It could be on the market by 2004.
Publication Name: USA Today
Subject: News, opinion and commentary
ISSN: 0734-7456
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Zinc spray shortens common cold
Article Abstract:
Gel-Tech of Woodland Hills, CA, has developed a new zinc nasal spray that cures common cold in a day and a half. The product called Zicam costs from $9 to $12 per bottle and is now available in many drug stores. The company said that a paid study involving 194 adult volunteers showed that common colds lasted for 1 1/2 days for those who used te full-strengh zinc spray, 3 1/2 days for those who took reduced dose of zinc and 10 days for the patients on placebo.
Publication Name: USA Today
Subject: News, opinion and commentary
ISSN: 0734-7456
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Not tonight honey, I took the placebo
Article Abstract:
A study financed by Viagra maker Pfizer indicates that the impotence drug does not improve the sexual response of women. The study was conducted among 577 Canadian and European women in a 12-week period. A medical expert opined that the findings were not surprising because while blood flow, which Viagra enhances, promotes erections in men, it may not relevant for women. Pfizer has scheduled another test involving menopausal women.
Publication Name: USA Today
Subject: News, opinion and commentary
ISSN: 0734-7456
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Bitove wins appeal on Pearson rent. Airlines play down talks on international routes. Senior CAI executives received 1% raises in 1998
- Abstracts: Caution flag on earnings. Special charge threatens health merger. Amid market chaos, busy Schwab bags 28% profit growth
- Abstracts: Celestica plans multibillion-dollar buying spree. Investors love Celestica's predictability
- Abstracts: Bombardier lands jet bonanza. Bombardier clinches record jet deal
- Abstracts: Book giants target Internet selling. Business forms maker aims to regain dominance. Boeing profit set on autopilot, but analysts fear a bumpy ride